Athira Pharma, Inc. (NASDAQ:ATHA) saw unusually-high trading volume on Thursday following a better than expected earnings announcement. Approximately 13,376 shares were traded during mid-day trading, a decline of 96% from the previous session’s volume of 352,162 shares.The stock last traded at $18.00 and had previously closed at $17.67.
The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.05.
Separately, Zacks Investment Research lowered Athira Pharma from a “buy” rating to a “hold” rating in a research report on Thursday, May 6th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $38.40.
The firm has a 50-day moving average of $18.19 and a 200 day moving average of $22.64.
About Athira Pharma (NASDAQ:ATHA)
Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and stop neurodegradation. Its lead product candidate is ATH-1017, a blood brain barrier-penetrating, small hepatocyte growth factor/MET activator that is in LIFT-AD Phase II/III and ACT-AD Phase II clinical trials for the treatment of mild-to-moderate Alzheimer's disease, as well as in clinical development for Parkinson's disease.
Featured Article: retirement calculator
Receive News & Ratings for Athira Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athira Pharma and related companies with MarketBeat.com's FREE daily email newsletter.